8/3/2019 Critical Appraisal of Journal Articles About Oral Ivermectin Versus Malathion Lotion for Difficult-Print

1/4

8/3/2019 Critical Appraisal of Journal Articles About Oral Ivermectin Versus Malathion Lotion for Difficult-Print

2/4

What are the results?

Therapy

How large was the treatment effect?

Absolute Risk Reduction/ Relative Risk

Reduction/ Number Needed to Treat

Analysis of the primary end point in the intention to-treat population, accordi

to the last-observation-carried-forward approach, showed that on day 15, 378

the 397 patients (95.2%) in the ivermectin group were free of head lice, compared with 352 of the 414 patients (85.0%) in the malathion gro

(absolute difference, 10.2 percentage points; 95% confidence interval [C

4.6 to 15.7; P

8/3/2019 Critical Appraisal of Journal Articles About Oral Ivermectin Versus Malathion Lotion for Difficult-Print

3/4

Will the results help me in my patient care?

Therapy

Were all clinically relevant outcomesconsidered?

Yes,Analysis of the primary end point in the intention to-treat population, according to the last-observation-carried-forward

approach, showed that on day 15, 378 of the 397 patients (95.2%)

in the ivermectin group were free of head lice, as compared with

352 of the 414 patients (85.0%) in the malathion group (absolute

difference, 10.2 percentage points; 95% confidence interval [CI],

4.6 to 15.7; P

8/3/2019 Critical Appraisal of Journal Articles About Oral Ivermectin Versus Malathion Lotion for Difficult-Print

4/4

In the general population, approximately 45 million people in

more than 30 countries have received 150 million doses of

ivermectin35 with no reported severe adverse events, although thedose was lower than that used to eradicate head lice in this study.

(Discussion, page 904).

Yogyakarta, 19 November 2011

Ko-Asisten, Preceptor,

Irmawati Masyhuda dr. Nafiah Chusniyati, Sp. KK,

M.Sc

4